At Incyte, our research is grounded in the relentless pursuit of scientific excellence and the conviction that the advancement of basic science can drive the discovery of innovative medicines for patients. Our world-class researchers are focused on transforming the treatment of cancer and inflammatory and autoimmune conditions, and are advancing a diversified portfolio of clinical candidates.


20 Molecular Targets

24 Clinical Candidates

7 Approved Products

Our Portfolio

Filter by:

Updated as of August 2, 2022

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.
1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 
4. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 5. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys; exclusive commercialization rights held by Incyte outside the U.S. 6. Approved in Europe 
7. Approved in Canada 8. European rights to Iclusig licensed from Takeda 9. In collaboration with MacroGenics
10. Discovery collaboration with Agenus 11. Worldwide rights to baricitinib licensed to Lilly 12. Approved in multiple territories globally 
13. Approved in Europe and Japan 14. Worldwide rights to capmatinib licensed to Novartis
1L, first-line; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; mAb, monoclonal antibody; MF, myelofibrosis; MLN, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory.

Clinical Trials

We have numerous clinical trials underway across Oncology and Inflammation & Autoimmunity research areas. Incyte-sponsored studies can be found at

Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please visit our online portal at

Learn more about our target molecules currently in clinical development

For questions concerning Investigator Initiated Research conducted outside of the US, please contact Incyte at

For questions concerning Investigator Initiated Research conducted in the US, please contact Incyte at